Company: PTHS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001753926-25-001764
Chunk: 78

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
 and referral patterns. Based on the Company’s interactions
with healthcare professionals (“HCPs”) to date, the Company believes HCPs would welcome this positioning of ZELSUVMI.

The
Company believes that ZELSUVMI fills a medical need in the market as the first safe and efficacious prescription medication for
molluscum contagiosum that can be administered outside of medical settings. Based on 2023 data from Veeva Compass, on an annual
basis, greater than 390,000 unique patients are affected by molluscum contagiosum and greater than 100,000 unique HCPs are treating
the disease in the United States. However, the Company believes this number underestimates the true number of cases due to a lack
of treatment options.

46

Sales
and Distribution Strategy

The
Company is marketing ZELSUVMI primarily to physicians with personal promotion and direct sales efforts with a dedicated sales
force supported by a product management team and critical support staff. The sales and marketing effort has focused on increasing
awareness, trial, adoption and usage of ZELSUVMI to targeted pediatricians, pediatric dermatologists and dermatologists. The Company
distributes ZELSUVMI via standard retail pharmacy chains, mail order and Amazon pharmacy utilizing a third-party logistics provider.
Based on the Company’s conversations with HCPs, the Company believes these distribution channels are the most preferred
by patients and HCPs. Critical to the launch and commercialization efforts of ZELSUVMI will be co-pay assistance and managing
co-pay and patient out-of-pocket costs as well as prescription “pull-through” strategies and tactics to ensure patient
access and utilization of ZELSUVMI.

Marketing
Strategy

The
Company is focusing sales and marketing efforts on expanding product awareness and trial of ZELSUVMI initially by means of personal
promotion by sales representatives to pediatric, pediatric dermatologist and dermatologist HCPs who have repeatedly included diagnosis
codes for molluscum contagiosum infection as part of their claims for reimbursement by health insurers for outpatient visits.
The Company also intends to expand its marketing strategies to include more non-personal promotion strategies and tactics focused
on patients and eventually to consumer segments. HCP marketing initiatives focus on driving adoption through targeted initiatives
like peer-to-peer education, data-driven digital advertising, and customized sales representative programs tailored to practice
needs such as understanding insurance coverage and product acquisition. Consumer marketing initiatives focus on expanding both
diagnosed and treated patient populations through